Kate Mckinley Buys 17,960 Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Stock

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) insider Kate Mckinley acquired 17,960 shares of the company’s stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $1.67 per share, for a total transaction of $29,993.20. Following the completion of the purchase, the insider now owns 17,960 shares of the company’s stock, valued at $29,993.20. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rani Therapeutics Price Performance

Shares of NASDAQ:RANI opened at $1.46 on Wednesday. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 2.34. The company has a 50-day moving average price of $2.21 and a 200 day moving average price of $2.80. Rani Therapeutics Holdings, Inc. has a 52 week low of $1.44 and a 52 week high of $8.75. The company has a market cap of $83.64 million, a P/E ratio of -1.38 and a beta of 0.05.

Institutional Trading of Rani Therapeutics

Institutional investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new position in Rani Therapeutics in the second quarter worth $81,000. King Luther Capital Management Corp increased its holdings in shares of Rani Therapeutics by 44.5% in the 3rd quarter. King Luther Capital Management Corp now owns 81,129 shares of the company’s stock valued at $175,000 after purchasing an additional 25,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Rani Therapeutics by 14.3% in the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company’s stock valued at $372,000 after purchasing an additional 21,527 shares during the period. Stifel Financial Corp boosted its holdings in Rani Therapeutics by 100.4% during the third quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock worth $583,000 after buying an additional 135,148 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Rani Therapeutics by 2.5% during the first quarter. Vanguard Group Inc. now owns 685,303 shares of the company’s stock worth $2,131,000 after buying an additional 16,956 shares during the period. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Rani Therapeutics in a research report on Tuesday, November 19th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Rani Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $11.71.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.